The Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry is a study collecting data on patients taking new medicines for Alzheimer's disease at special memory clinics. Alzheimer's is a brain disease that affects memory and thinking. Researchers want to see how well these new medicines, called anti-amyloid monoclonal antibodies, work in real-life situations. These medicines were recently approved by the FDA, which stands for Food and Drug Administration, a government body that checks if medicines are safe to use. The study will use the Georgia Memory Net program, which helps people get diagnosed and treated for memory problems.

• This study is about collecting observations, so participants will not receive any new treatments.
• Participants will be watched throughout their initial treatment and follow-up visits.
• To join, you must have mild memory issues, be between 50-90 years old, and meet other health criteria.

Participation involves regular check-ups, including brain scans and blood tests, to monitor your health while on the medicine. This study helps researchers learn more about the safety and effectiveness of new Alzheimer's treatments.